BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Industry, Sector and Symbol:
- Sector: Basic Materials
- Industry: Chemicals - Major Diversified
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: BIOA
- Previous Close: $3.41
- 50 Day Moving Average: $4.45
- 200 Day Moving Average: $4.41
- 52-Week Range: $2.86 - $6.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.75
- P/E Growth: 0.00
- Market Cap: $98.33M
- Outstanding Shares: 28,836,000
- Beta: 2.69
- Net Margins: -227.35%
- Return on Equity: -63.08%
- Return on Assets: -21.80%
Companies Related to BioAmber:
- Debt-to-Equity Ratio: 0.58%
- Current Ratio: 0.80%
- Quick Ratio: 0.71%
What is BioAmber's stock symbol?
BioAmber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."
Where is BioAmber's stock going? Where will BioAmber's stock price be in 2017?
3 brokerages have issued 12-month price objectives for BioAmber's stock. Their forecasts range from $5.50 to $17.00. On average, they expect BioAmber's share price to reach $11.25 in the next year.
When will BioAmber announce their earnings?
BioAmber is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns BioAmber stock?
BioAmber's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (3.90%), Royce & Associates LP (2.86%), Baillie Gifford & Co. (2.01%) and Raymond James Financial Services Advisors Inc. (0.11%). Company insiders that own BioAmber stock include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Michael A Hartmann and Raymond J Land.
Who bought BioAmber stock? Who is buying BioAmber stock?
BioAmber's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC and Royce & Associates LP. Company insiders that have bought BioAmber stock in the last two years include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Michael A Hartmann and Raymond J Land.
How do I buy BioAmber stock?
Shares of BioAmber can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioAmber stock cost?
One share of BioAmber stock can currently be purchased for approximately $3.41.